Retrospective study of lyso-Gb3 plasma concentration in Fabry patients receiving ERT/Replagal

Trial Profile

Retrospective study of lyso-Gb3 plasma concentration in Fabry patients receiving ERT/Replagal

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Agalsidase alfa (Primary)
  • Indications Fabry's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Oct 2016 Status changed from recruiting to completed.
    • 01 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top